Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal amikacin for inhalation in refractory MAC lung infection
2014-005010-31Phase 3Completed
- Sponsor
- Insmed Incorporated
- Start
- Feb 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amikacin in nontuberculous mycobacterial lung disease (2 arms), sponsored by Insmed Incorporated. Primary endpoint: Culture conversion by Month 6. Started Feb 2015; status: completed.
02
Drugs
amikacin
03
Conditions
nontuberculous mycobacterial lung disease
Beyond the preview
Go deeper on 2014-005010-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005010-31.